Aclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema Trial
Portfolio Pulse from Vandana Singh
Aclaris Therapeutics Inc (NASDAQ:ACRS) reported mixed results from its Phase 2b study of ATI-1777 for atopic dermatitis. The study met its primary efficacy endpoint with statistical significance for the 2% twice-daily dosage compared to the vehicle. However, the once-daily dosage showed a trend toward significance but was not statistically superior. Post-hoc analysis indicated a significant reduction in EASI score for moderate to severe cases. The drug was well tolerated with minimal exposure levels and no significant safety issues. ACRS shares dropped 22.5% to $0.99 following the news.
January 10, 2024 | 4:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aclaris Therapeutics' stock fell sharply by 22.5% after announcing mixed results from its ATI-1777 eczema treatment study, despite meeting the primary efficacy endpoint.
The stock price of Aclaris Therapeutics dropped significantly due to the mixed results of the ATI-1777 study, which could impact investor confidence in the drug's potential for approval and commercial success. The primary endpoint was met, which is positive, but the lack of statistical superiority in the once-daily dosage and the market's reaction to the news are likely to have a negative short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100